Top 15 Biotech Companies Leading the NAMs Revolution
Key Takeaways
- The global organ-on-chip market is projected to exceed $1.6 billion by 2028, growing at 30%+ CAGR
- Major pharma companies (Roche, Pfizer, J&J, Sanofi) are actively partnering with NAMs technology providers
- Three categories dominate: organ-on-chip platforms, organoid service providers, and computational/in silico companies
- Post-FDA Modernization Act, venture capital investment in NAMs startups increased 40% year-over-year
The passage of the FDA Modernization Act catalyzed investment and commercial adoption of new approach methodologies. These 15 companies represent the leading edge of the technology stack that will define the next generation of preclinical drug development.
Organ-on-Chip Platform Companies
1. Emulate Inc.
Spun out of the Wyss Institute at Harvard, Emulate developed the first organ-on-chip platform to receive FDA qualification through the ISTAND program. Their product line includes Lung-Chip, Liver-Chip, Intestine-Chip, Kidney-Chip, and Brain-Chip models. Emulate has partnerships with Roche, Johnson & Johnson, and Takeda. Their validation data demonstrating superior predictiveness over animal models for liver toxicity has been widely cited in the regulatory literature.
2. Mimetas
Mimetas developed the OrganoPlate, a 96-well plate format organ-on-chip system that uses gravity-driven flow instead of external pumps. This design enables higher throughput screening compatible with standard laboratory liquid handling robots. Their kidney tubule and blood-brain barrier models are used by Sanofi, Galapagos, and academic institutions globally. The pump-free design makes their platform particularly accessible for labs transitioning from traditional cell culture.
3. CN Bio Innovations
CN Bio's PhysioMimix platform is the leading liver-on-chip system for DILI (drug-induced liver injury) assessment. Their single-organ and multi-organ configurations support long-term culture (28+ days) and incorporate immune components. CN Bio has demonstrated NASH (non-alcoholic steatohepatitis) disease modeling on-chip, a critical capability given the large number of NASH drugs currently in development.
4. TissUse GmbH
TissUse specializes in multi-organ chip systems connecting up to four organ models in a single circulatory system. Their HUMIMIC platform enables ADME (absorption, distribution, metabolism, excretion) studies in a human-relevant context. They are one of the few companies offering connected skin-liver-kidney-intestine systems for systemic toxicity assessment.
5. Hesperos
Founded by MPS pioneer Michael Shuler, Hesperos builds multi-organ human-on-chip systems with functional readouts including cardiac contractility, neural activity, and barrier integrity. Their technology integrates real-time sensing of organ function, enabling dynamic drug response measurement rather than endpoint-only analysis.
Organoid and 3D Tissue Companies
6. HUB Organoids
Founded by Hans Clevers, HUB Organoids holds foundational intellectual property for adult stem cell-derived organoid technology. Their organoid biobank includes patient-derived tumor organoids across 20+ cancer types, used for personalized drug screening. Major pharma partnerships include AbbVie, Roche, and Boehringer Ingelheim.
7. InSphero
InSphero's GravityTRAP platform produces standardized 3D microtissues (spheroids) for liver toxicity, metabolic disease, and oncology applications. Their liver microtissues maintain metabolic function for 28+ days, enabling repeat-dose toxicity studies. InSphero has established itself as a CRO (contract research organization) partner for pharma companies transitioning to 3D models.
8. Organovo
Organovo pioneered 3D bioprinting of functional human tissues. Their ExVive liver tissue model was the first bioprinted tissue used in preclinical drug testing. While the company has pivoted toward therapeutic tissue engineering, their contribution to establishing 3D tissue models as viable preclinical tools was foundational for the NAMs field.
9. MatTek Corporation
MatTek's EpiDerm and EpiIntestinal tissue models are among the most widely used in vitro alternatives to animal testing for dermal and intestinal toxicity. EpiDerm is accepted by the OECD (Test Guideline 439) as a validated replacement for the rabbit Draize skin irritation test. Their models represent the gold standard for regulatory-accepted in vitro tissue models.
10. Crown Bioscience
Crown Bioscience maintains one of the world's largest collections of patient-derived tumor organoids (1,500+ models across 20+ tumor types). Their HUB-licensed organoid platform enables personalized oncology drug screening, and their pharmacogenomic database links organoid drug response data to patient clinical outcomes.
Computational and In Silico Companies
11. Recursion Pharmaceuticals
Recursion combines high-content imaging with machine learning to map drug effects at the cellular level. Their platform generates terabytes of phenotypic data per week, using computer vision to identify drug mechanisms without prior hypothesis. Recursion has advanced multiple drug candidates discovered entirely through their computational platform into clinical trials.
12. Insilico Medicine
Insilico Medicine uses generative chemistry and deep learning to design novel drug candidates. Their platform identified a novel target for idiopathic pulmonary fibrosis and generated a drug candidate in under 18 months - a process that typically takes 4-5 years. Their clinical candidate INS018_055 became one of the first entirely computationally-discovered drugs to enter Phase II clinical trials.
13. Quris
Quris combines patient-derived stem cell chips with machine learning to predict clinical trial outcomes before human testing begins. Their platform has demonstrated the ability to predict drug toxicity with clinical-grade accuracy by testing drugs on chip-based organ models derived from diverse patient populations, then using proprietary algorithms to extrapolate population-level safety profiles.
14. BioIVT
BioIVT provides the biological materials that power much of the NAMs ecosystem: human hepatocytes, primary cells, plasma, serum, and tissue samples. Their ADME and toxicology testing services integrate human-derived materials into preclinical workflows, serving as critical infrastructure for companies building human-relevant models.
15. Kirkstall
Kirkstall's Quasi Vivo system provides a modular, connected cell culture platform that maintains physiological flow between multiple tissue types. Their open-format design allows researchers to use their own cell models while adding the fluidic connectivity essential for multi-organ studies. The affordability and flexibility of their platform has made them popular in academic research settings.
Market Landscape
The combined addressable market for NAMs technologies is projected to exceed $5 billion by 2030, driven by:
- Regulatory catalysts (FDA Modernization Act, EPA NAMs strategy, EU directive on animal testing)
- Cost pressures in drug development (average $2.6 billion per approved drug)
- Failure rate reduction potential (90%+ failure rate of current animal-based predictions)
- Increased venture capital interest post-Modernization Act (40%+ YoY investment growth)
- Expanding pharma partnerships as validation data accumulates
Explore Company Profiles
Patient Analog maintains detailed profiles of 19 leading biotech companies in the NAMs space.
View All Companies Market Analysis